Securities Code: 002275
Securities Abbreviation: Guilin Sanjin
Announcement No.: 2026-018
Guilin Sanjin Pharmaceutical Co., Ltd.
Announcement on Wholly-Owned Subsidiary's Product Being Selected in the 12th Batch of National Centralized Drug Procurement
The Company and all members of the Board of Directors guarantee that the information disclosed in this report is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.
On July 31, 2026, Guilin Sanjin Pharmaceutical Co., Ltd. (hereinafter referred to as the Company) and its wholly-owned subsidiary, Sanjin Group Hunan Sanjin Pharmaceutical Co., Ltd. (hereinafter referred to as Hunan Sanjin), participated in the bidding for the 12th batch of national centralized drug procurement with volume-based purchasing organized by the National Joint Procurement Office for Drugs (hereinafter referred to as the Joint Procurement Office).